Search results
Results from the WOW.Com Content Network
COVID-19 vaccines gave Moderna, Pfizer and Johnson & Johnson a boost — but are the stocks still a good investment in 2021? Here's what to consider before buying in.
Unlike the COVID-19 pandemic, when the U.S. government subsidized private companies to make the COVID-19 vaccine, the government actually has a stockpile of H5N1 virus candidates that could be ...
An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, and Pfizer fell almost 2%.
As the omicron variant picks up speed, investors are turning to vaccine stocks that could potentially profit. The U.S. is currently averaging 121,107 new Covid-19 cases per day and showing no ...
Stocks of coronavirus vaccine could run out at the end of January unless new ones such as the Oxford jab are approved, a former minister has warned. Former health secretary Jeremy Hunt told the ...
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement ...
The mass COVID-19 vaccination drive has sent the stocks of publicly traded firms developing the vaccine […] You can skip our comprehensive analysis of the biopharma industry and go directly to ...